We did not find any difference of differential expression of the other immune target genes (e.g., LAG3, CTLA4, or HAVCR2) in BCC compared to healthy skin tissue in the presence or absence of high As exposure that could suggest the potential use of other immune checkpoint inhibitors targeting those genes. This evidence concerns the gene LAG3 and skin basal cell carcinoma.